REGULATORY COMPLIANCE – Page 29

Electronic signatures misused during inspection walkthrough – CAPA and revalidation strategy

Identifying the misuse of electronic signatures often starts with recognizing certain symptoms or signals. Key indicators include:Click to read the full article.

Deviation handling weak during sponsor oversight – preventing repeat GLP findings

Identifying symptoms or signals indicative of weak deviation handling is the first step towards a robust response. Symptoms might manifest as:Click to read the full article.

CSV compliance weak during site expansion – regulatory deficiency risk

Identifying symptoms of weak CSV compliance during site expansion is critical for timely interventions. Below are common signals to watch for:Click to read the full article.

Hybrid paper-electronic workflows uncontrolled during validation lifecycle – 21 CFR Part 11 compliance gaps

Identifying the warning signs of uncontrolled workflows is paramount. Some common symptoms include:Click to read the full article.

Change impact not assessed during lifecycle management – inspection evidence expectations

Identifying symptoms of change impact not properly assessed can be challenging but is crucial for ensuring compliance and product quality. Common symptoms or signals that may indicate potential issues include:Click…

ERES controls not implemented during system upgrade – risk-based ERES remediation

Risk-Based Remediation for Inadequate ERES Controls During System Upgrade In the rapidly evolving landscape of pharmaceutical compliance, the implementation of Electronic Records and Electronic Signatures (ERES) controls during system upgrades…

Requalification overdue during inspection readiness – inspection evidence expectations

Identifying symptoms early can mitigate risks associated with overdue requalification. Here are some signals to watch for:Click to read the full article.

ERES controls not implemented during system operation – preventing repeat Part 11 findings

Recognizing early signs of ERES control failures is crucial for immediate intervention. Symptoms may manifest as:Click to read the full article.

Test article accountability issue during routine studies – inspection deficiency risk analysis

Recognizing symptoms of test article accountability issues is the first line of defense in preventing inspection deficiencies. The following signals can indicate potential problems:Click to read the full article.

Validation gaps identified during system upgrades – CAPA and revalidation strategy

Identifying symptoms early is crucial to mitigate risks associated with validation gaps. Here are some common signals that may indicate potential validation issues:Click to read the full article.

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – 21 CFR Part 11 compliance gaps

Identifying symptoms related to uncontrolled hybrid workflows is crucial for proactive management. Watch for the following signs:Click to read the full article.

Incomplete validation lifecycle during lifecycle management – preventing repeat validation findings

Identifying symptoms of an incomplete validation lifecycle is crucial for prompt intervention. Common signals include:Click to read the full article.